A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China

被引:20
|
作者
Zhu, L. [1 ,2 ]
Tse, C. -H. [1 ,2 ]
Wong, V. W. -S. [1 ,2 ]
Chim, A. M. -L. [1 ,2 ]
Leung, K. -S. [3 ]
Chan, H. L. -Y. [1 ,2 ]
机构
[1] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Inst Digest Dis, Shatin, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Dept Engn & Comp Sci, Hong Kong, Hong Kong, Peoples R China
关键词
chronic hepatitis B; cirrhosis; fibrosis; phylogenetic analysis; polymerase chain reaction; sequencing;
D O I
10.1111/j.1365-2893.2008.00967.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We aimed to study the distribution of hepatitis B virus (HBV) genotypes/subgenotypes in different parts of China and their clinical impact on the severity of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Residual serum samples from a cohort of HBeAg-negative chronic hepatitis B patients in Hong Kong, Shanghai and Beijing were studied. Complete HBV genomic sequencing was performed for phylogenetic tree analysis and determination of HBV mutations was carried out. Mutations associated with severe liver fibrosis (Ishak score 4 or more) were selected by computerized information gain criteria. Genotype B (all subgenotype Ba) HBV was present in 19 of 45 (42%), 12 of 31 (39%) and 5 of 25 (20%) patients in Hong Kong, Shanghai and Beijing, respectively (P = 0.16). Ninety-seven per cent of genotype C HBV in Shanghai and Beijing belonged to subgenotype Ce whereas 69% of genotype C patients in Hong Kong belonged to subgenotype Cs (P < 0.001). Patients infected by subgenotype Cs had the lowest serum albumin and highest alanine aminotransferase levels compared with subgenotype Ce and Ba. Patients infected by subgenotype Cs also had more severe histological necroinflammation than subgenotype Ce. Two HBV mutations were identified to associate with severe liver fibrosis (G2858C and C2289A) and one mutation was protective against severe liver fibrosis (T2201C). The T2201C mutation was found exclusively among patients (21 of 46 patients, 45%) infected by HBV subgenotype Ce. The clinical differences in HBeAg-negative chronic hepatitis B in China may be influenced by different distribution of subgenotype C HBV.
引用
收藏
页码:449 / 458
页数:10
相关论文
共 50 条
  • [21] Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis
    Zhang, Zhan-qing
    Wang, Yan-bing
    Lu, Wei
    Liu, Dan-ping
    Shi, Bi-sheng
    Zhang, Xiao-nan
    Huang, Dan
    Li, Xiu-fen
    Zhou, Xin-lan
    Ding, Rong-rong
    ANNALS OF LABORATORY MEDICINE, 2019, 39 (01) : 67 - 75
  • [22] Core Promoter and Pre-Core Variants of the Hepatitis B Virus (HBV) Are Frequent in Chronic Hepatitis B HBeAg-Negative Patients Infected by Genotypes A and D
    Reuter, Tania
    Gomes-Gouvea, Michele Soares
    Chuffi, Samira
    Duque, Ulisses Horst
    Perini, Waltesia
    Azevedo, Raymundo Soares
    Pinho, Joao Renato Rebello
    Lewis-Ximenez, Lia L.
    Villar, Livia Melo
    Espul, Carlos Alberto
    Pujol, Flor H.
    Roman, Sonia
    VIRUSES-BASEL, 2023, 15 (12):
  • [23] Detection of Hepatitis B Virus Covalently Closed Circular DNA in the Plasma of Iranian HBeAg-Negative Patients With Chronic Hepatitis B
    Tajik, Zahra
    Keyvani, Hossein
    Bokharaei-Salim, Farah
    Zolfaghari, Mohammad Reza
    Fakhim, Shahin
    Keshvari, Maryam
    Alavian, Seyed Moayed
    HEPATITIS MONTHLY, 2015, 15 (09)
  • [24] HbeAg-negative chronic hepatitis B results in more severe liver disease than HBeAg-positive chronic hepatitis B
    Mahtab, M.
    Rahman, S.
    Khan, M.
    LIVER INTERNATIONAL, 2006, 26 : 55 - 55
  • [25] HBSAG SEROCOVERSION UNDER LAMIVUDINE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B
    Seven, Gulseren
    Idilman, Ramazan
    Bozkus, Yusuf
    Cinar, Kubilay
    Kabacam, Gokhan
    Yakut, Mustafa
    Bozdayi, A. Mithat
    Yurdaydin, Cihan
    HEPATOLOGY, 2010, 52 (04) : 545A - 546A
  • [26] Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B
    Rizzetto, M
    Tassopoulos, NC
    Goldin, RD
    Esteban, R
    Santantonio, T
    Heathcote, EJ
    Lagget, M
    Taak, NK
    Woessner, MA
    Gardner, SD
    JOURNAL OF HEPATOLOGY, 2005, 42 (02) : 173 - 179
  • [27] Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia
    Victoria, Flamir da Silva
    Costa de Oliveira, Cintia Mara
    Victoria, Marilu Barbieri
    Victoria, Cristian Barbieri
    Lima Ferreira, Luis Carlos
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (01): : 27 - 37
  • [28] Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
    Lai, CL
    Shouval, D
    Lok, AS
    Chang, TT
    Cheinquer, H
    Goodman, Z
    DeHertogh, D
    Wilber, R
    Zink, RC
    Cross, A
    Colonno, R
    Fernandes, L
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10): : 1011 - 1020
  • [29] Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon
    Brunetto, MR
    Oliveri, F
    Colombatto, P
    Coco, B
    Ciccorossi, P
    Bonino, F
    JOURNAL OF HEPATOLOGY, 2003, 39 : S164 - S167
  • [30] Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients
    Kwak, Min-Sun
    Cho, Eun Ju
    Jang, Eun Sun
    Lee, Jeong-Hoon
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Lee, Hyo-Suk
    DIGESTION, 2011, 84 : 23 - 28